中华妇产科杂志
中華婦產科雜誌
중화부산과잡지
CHINESE JOUNAL OF OBSTETRICS AND GYNECOLOGY
2010年
10期
772-774
,共3页
谭志琴%刘伏香%唐海林%苏琦
譚誌琴%劉伏香%唐海林%囌琦
담지금%류복향%당해림%소기
子宫内膜肿瘤%微RNAs%聚合酶链反应
子宮內膜腫瘤%微RNAs%聚閤酶鏈反應
자궁내막종류%미RNAs%취합매련반응
Endometrial neoplasms%MicroRNAs%Polymerase chain reaction
目的 探讨hsa-miR-155在子宫内膜癌患者血清中的表达及其临床意义.方法 选择2008年9月至2009年12月间解放军第一六九医院妇产科收治的44例子宫内膜癌患者,以同期12例健康志愿者作为对照,应用实时荧光定量PCR技术检测子宫内膜癌患者和健康志愿者血清hsa-miR-155的表达水平(以倍数表示),分析hsa-miR-155表达与子宫内膜癌临床病理指标间的关系.结果 相对于健康志愿者,子宫内膜癌患者血清hsa-miR-155的表达水平为(3.9±0.7)倍,两者比较,差异有统计学意义(P＜0.01).其中,高、中、低分化子宫内膜癌患者血清hsa-miR-155的表达水平分别为(3.7±0.6)、(3.9±0.6)、(3.7±0.6)倍,3者分别比较,差异均无统计学意义(P＞0.05);子宫内膜样腺癌与非子宫内膜样腺癌患者血清hsa-miR-155的表达水平分别为(3.8±0.6)、(3.9±0.6)倍,两者比较,差异无统计学意义(P＞0.05);Ⅰ～Ⅱ、Ⅲ～Ⅳ期子宫内膜癌患者血清hsa-miR-155的表达水平分别为(2.1±0.4)、(5.6±0.8)倍,两者比较,差异有统计学意义(P＜0.01);有、无盆腔淋巴结转移子宫内膜癌患者血清hsa-miR-155的表达水平分别为(5.5±0.5)、(1.9±0.2)倍,两者比较,差异有统计学意义(P＜0.01).结论 hsa-miR-155与子宫内膜癌的发生、转移密切相关,有可能成为判断子宫内膜癌疗效及预后的潜在生物学指标.
目的 探討hsa-miR-155在子宮內膜癌患者血清中的錶達及其臨床意義.方法 選擇2008年9月至2009年12月間解放軍第一六九醫院婦產科收治的44例子宮內膜癌患者,以同期12例健康誌願者作為對照,應用實時熒光定量PCR技術檢測子宮內膜癌患者和健康誌願者血清hsa-miR-155的錶達水平(以倍數錶示),分析hsa-miR-155錶達與子宮內膜癌臨床病理指標間的關繫.結果 相對于健康誌願者,子宮內膜癌患者血清hsa-miR-155的錶達水平為(3.9±0.7)倍,兩者比較,差異有統計學意義(P＜0.01).其中,高、中、低分化子宮內膜癌患者血清hsa-miR-155的錶達水平分彆為(3.7±0.6)、(3.9±0.6)、(3.7±0.6)倍,3者分彆比較,差異均無統計學意義(P＞0.05);子宮內膜樣腺癌與非子宮內膜樣腺癌患者血清hsa-miR-155的錶達水平分彆為(3.8±0.6)、(3.9±0.6)倍,兩者比較,差異無統計學意義(P＞0.05);Ⅰ～Ⅱ、Ⅲ～Ⅳ期子宮內膜癌患者血清hsa-miR-155的錶達水平分彆為(2.1±0.4)、(5.6±0.8)倍,兩者比較,差異有統計學意義(P＜0.01);有、無盆腔淋巴結轉移子宮內膜癌患者血清hsa-miR-155的錶達水平分彆為(5.5±0.5)、(1.9±0.2)倍,兩者比較,差異有統計學意義(P＜0.01).結論 hsa-miR-155與子宮內膜癌的髮生、轉移密切相關,有可能成為判斷子宮內膜癌療效及預後的潛在生物學指標.
목적 탐토hsa-miR-155재자궁내막암환자혈청중적표체급기림상의의.방법 선택2008년9월지2009년12월간해방군제일륙구의원부산과수치적44례자궁내막암환자,이동기12례건강지원자작위대조,응용실시형광정량PCR기술검측자궁내막암환자화건강지원자혈청hsa-miR-155적표체수평(이배수표시),분석hsa-miR-155표체여자궁내막암림상병리지표간적관계.결과 상대우건강지원자,자궁내막암환자혈청hsa-miR-155적표체수평위(3.9±0.7)배,량자비교,차이유통계학의의(P＜0.01).기중,고、중、저분화자궁내막암환자혈청hsa-miR-155적표체수평분별위(3.7±0.6)、(3.9±0.6)、(3.7±0.6)배,3자분별비교,차이균무통계학의의(P＞0.05);자궁내막양선암여비자궁내막양선암환자혈청hsa-miR-155적표체수평분별위(3.8±0.6)、(3.9±0.6)배,량자비교,차이무통계학의의(P＞0.05);Ⅰ～Ⅱ、Ⅲ～Ⅳ기자궁내막암환자혈청hsa-miR-155적표체수평분별위(2.1±0.4)、(5.6±0.8)배,량자비교,차이유통계학의의(P＜0.01);유、무분강림파결전이자궁내막암환자혈청hsa-miR-155적표체수평분별위(5.5±0.5)、(1.9±0.2)배,량자비교,차이유통계학의의(P＜0.01).결론 hsa-miR-155여자궁내막암적발생、전이밀절상관,유가능성위판단자궁내막암료효급예후적잠재생물학지표.
Objective To investigate the expression of the hsa-miR-155 in serum of endometrial cancer and its clinical significance. Methods Collected 44 cases blood specimens before surgery operation from Sep. 2008 to Dec. 2009, and collected 12 cases blood specimens from the health of volunteers in comparison. Real time quantity PCR was used to detect the expression of hsa-miR-155 in those specimens and analyzed clinical pathological with the expression of hsa-mir-155 in endometrial cancer. Results The expression of hsa-miR-155 was (3.9 ±0.7) in endometrial cancer, which was significantly higher than that in control group( P ＜ 0.01 ). The expressions of hsa-miR-155 were ( 3.7 ± 0.6 ), ( 3.9 ± 0.6 ) and ( 3.7 ±0.6)times in well, moderately and poorly differentiated endometrial cancer, respectively,while there were not significant difference ( P ＞ 0.05 ). The expressions were ( 3.8 ± 0.6 ) and ( 3.9 ± 0.6 ) times between endometrioid adenocarcinoma and non-endometrioid adenocarcinoma, and there were significant difference (P ＞ 0.05). The expressions were ( 2.1 ± 0.4 ) and ( 5.6 ± 0.8 ) times in stage Ⅰ - Ⅱ and Ⅲ - Ⅳ endometrial cancer, respectively, in which there were significant difference (P ＜ 0.05 ). The expressions of hsa-miR-155 were (5.5 ± 0.5 ) and ( 1.9 ± 0.2) times between lymph node metastasis and without lymph node metastasis in endometrial cancer, in which there were significant difference (P ＜ 0.01 ). Conclusion Hsa-miR-155 may play an important role in the proliferation, and metastasis of endometrial cancer, which may be a indicator in the diagnosis and prognosis of endometrial cancer and may be used as a predictive biomarker.
